方法：增殖期糖尿病视网膜病变患者50例68眼，按照治疗选择的自然状态分为两组，试验1组34例41眼：球内注射贝伐单抗1.25mg(0.05mL)/次，试验2组16例27眼球内注射曲安奈德4mg(0.1mL)/次，两组分别于球内注药前及注药后1，3，6mo再次注药或行玻璃体切割前抽取玻璃体液0.3mL，并以黄斑裂孔患者20例20眼为空白对照组，注药后根据一定纳入标准，选取各试验组符合条件的患者采集的标本行酶联免疫吸附试验检测VEGI、IL-1β及VEGF的质量浓度，并进行组间比较，所得数据采用SPSS19.0统计软件分析。

结果：与对照组相比，试验组患者注药前玻璃体腔中VEGI浓度降低，IL-1β及VEGF浓度显著升高，组间比较差异有统计学意义(P<0.05)； 试验组注药后随着时间延长及注药次数增加，IL-1β及VEGF浓度降低，VEGI浓度逐渐升高，差异有统计学意义(P<0.05)； 临床观察提示：试验组注药后黄斑水肿程度较前减轻，试验2组远期效果好于试验1组(P<0.05)。

结论：VEGI可能与VEGF及IL-1β协同作用参与了增殖性糖尿病视网膜病变的发生发展。

METHODS: Fifty patients with 68 eyes were randomly divided into 2 groups according its treatment situation. Thirty-four patients with 41 eyes were chosen as group one, who were treated with bevacizumab 1.25mg(0.05mL)per eye, and group 2 composed of 16 patients(27 eyes), who were accepted intravitreal injection of triamcinolone acetonide 4mg(0.1mL). Twenty patients(20 eyes), who were diagnosed as macula hole, were chosen for control group. Certain patients were collected as target population according to the inclusion criteria. VEGI, IL-1β and VEGF in vitreous were determined by ELISA, in which the samples of 0.3mL vitreous were collected before intravitreal injection or at 1, 3, 6mo post-injection in the two groups. And the data obtained between groups were compared by SPSS 19.0 statistical software.

RESULTS: Significant difference was found between control group and experimental groups in which VEGI decreased while IL-1β and VEGF increased before injection(P<0.05). However, VEGI increased but IL-1β and VEGF decreased compared with control group after intravitreal injection(P<0.05). The clinical observation showed that the macula edema reduced in experimental groups post-injection, and experimental group 2 was better than experimental group 1 in the long-term results(P<0.05).

CONCLUSION: VEGI is found accompanied with VEGF and IL-1β in the vitreous, and they may play an important role in the pathogenesis of PDR.